Rockefeller Capital Management
RXRX icon

Rockefeller Capital Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Rockefeller Capital Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$803K Buy
261,513
+227,224
+663% +$878K ﹤0.01% 1726
2025
Q4 		$140K Sell
34,289
-19,145
-36% -$94.8K ﹤0.01% 2541
2025
Q3 		$261K Sell
53,434
-163,331
-75% -$858K ﹤0.01% 2088
2025
Q2 		$1.1M Sell
216,765
-170,691
-44% -$839K ﹤0.01% 1287
2025
Q1 		$2.05M Buy
387,456
+105,534
+37% +$769K 0.01% 1033
2024
Q4 		$1.91M Buy
281,922
+215,283
+323% +$1.45M ﹤0.01% 1028
2024
Q3 		$439K Buy
+66,639
New +$478K ﹤0.01% 1465
2024
Q2 		– Sell
-21,246
Closed -$212K – 1721
2024
Q1 		$212K Buy
+21,246
New +$237K ﹤0.01% 1653
2023
Q1 		– Sell
-2,378
Closed -$18K – 3536
2022
Q4 		$18K Sell
2,378
-4,941
-68% -$48.5K ﹤0.01% 2849
2022
Q3 		$77K Buy
7,319
+1,378
+23% +$14K ﹤0.01% 2136
2022
Q2 		$48K Sell
5,941
-6,647
-53% -$44.5K ﹤0.01% 2315
2022
Q1 		$90K Buy
12,588
+2,191
+21% +$23.3K ﹤0.01% 2031
2021
Q4 		$178K Buy
10,397
+8,347
+407% +$157K ﹤0.01% 1691
2021
Q3 		$47K Buy
2,050
+1,050
+105% +$29.8K ﹤0.01% 2171
2021
Q2 		$36K Buy
+1,000
New +$29.6K ﹤0.01% 2232

Other funds holding RXRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Rockefeller Capital Management's RXRX Position: Q1 2026 in Review

Rockefeller Capital Management increased its Recursion Pharmaceuticals (RXRX) stake by 663% in Q1 2026, buying an estimated $878K and bringing the position to 261,513 shares worth $803K. The position accounts for ﹤0.01% of the portfolio, ranked #1726.

Rockefeller Capital Management first reported a position in RXRX in Q2 2021 and has held it in 15 quarters since. The position peaked at $2.05M in Q1 2025. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • Rockefeller Capital Management held 261,513 shares of Recursion Pharmaceuticals worth $803K as of Q1 2026.
  • Rockefeller Capital Management bought 227,224 Recursion Pharmaceuticals shares in Q1 2026, an estimated $878K.
  • Recursion Pharmaceuticals made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q1 2026, its #1726 holding.
  • Rockefeller Capital Management first reported a position in Recursion Pharmaceuticals in Q2 2021 and has held it in 15 quarters since.
  • Rockefeller Capital Management's Recursion Pharmaceuticals position peaked at $2.05M in Q1 2025.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Rockefeller Capital Management's 13F filing for Q1 2026, filed 14 May 2026.